SCHEMBL13627973

SCHEMBL13627973

N#Cc1ccccc1CN1C(=O)/C(=N\O)c2cc(F)ccc21

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.47
TRPA1 O75762 1/20 0.42
GRIN1 Q05586 3/20 0.39
GRIN2B Q13224 3/20 0.39
MAPK14 Q16539 1/20 0.38
TACR1 P25103 2/20 0.38
PARK7 Q99497 2/20 0.38
NOX4 Q9NPH5 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
THRB P10828 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627952 0.86 ALDH1A1 (0.41) NOX4ALDH1A1SMN1; SMN2THRBCA12
SCHEMBL13627947 0.85 CHRM5 (0.52) CHRM5TRPA1PARK7ALDH1A1THRB
SCHEMBL13627936 0.80 TRPA1 (0.62) CHRM5TRPA1PARK7ALDH1A1
SCHEMBL13627949 0.79 ACHE (0.55) CHRM5TRPA1TACR1ALDH1A1SMN1; SMN2
SCHEMBL13627937 0.77 CHRM5 (0.55) CHRM5TRPA1PARK7ALDH1A1CA12
SCHEMBL13627946 0.76 UBE2N (0.56) CHRM5TRPA1PARK7ALDH1A1CA12
SCHEMBL13910782 0.75 CHRM5 (0.41) CHRM5TRPA1PARK7ALDH1A1CA12
SCHEMBL13627987 0.75 GRIN1 (0.38) GRIN1GRIN2BNOX4ALDH1A1SMN1; SMN2
SCHEMBL13910783 0.74 TRPA1 (0.53) CHRM5TRPA1PARK7ALDH1A1CA12
SCHEMBL13627907 0.74 CA1 (0.49) CHRM5ALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CHRM5 4815/4885TRPA1 4561/4885GRIN1 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.